AstraZeneca has convinced a Delaware federal judge to throw out a jury's decision that the company owes USD 107.5 million for infringing cancer-drug patents belonging to Wyeth, a subsidiary of Pfizer. U.S. District Judge Matthew Kennelly determined that the two patents Pfizer claimed were infringed by AstraZeneca's lung-cancer drug Tagrisso were invalid.

Tagrisso earned UK-based AstraZeneca nearly $5.8 billion in revenue last year, according to a company report.

AstraZeneca has convinced a Delaware federal judge to throw out a jury's decision that the company owes USD 107.5 million for infringing cancer-drug patents belonging to Wyeth, a subsidiary of Pfizer. U.S. District Judge Matthew Kennelly determined that the two patents Pfizer claimed were infringed by AstraZeneca's lung-cancer drug Tagrisso were invalid.

Spokespeople for Pfizer and AstraZeneca did not immediately respond to requests for comment on the decision.

New York-based Pfizer, which acquired Wyeth in 2009, sued AstraZeneca in 2021. It said that AstraZeneca's Tagrisso infringed patents related to the breast-cancer drug Nerlynx, which Puma Biotechnology makes with a license to Pfizer's patents.

Tagrisso earned UK-based AstraZeneca nearly $5.8 billion in revenue last year, according to a company report.